Intracytoplasmic Sperm Injection (ICSI) is an advanced reproductive technology performed alongside in vitro fertilization (IVF), in which a single selected spermatozoon is injected directly into the cytoplasm of a mature oocyte using specialized microinjection equipment to facilitate fertilization. ICSI is frequently utilized in cases involving male factor infertility. The objective of the procedure is to cultivate resulting embryos for subsequent uterine transfer. While the broader preparation and culture steps resemble standard IVF, the laboratory fertilization mechanism is modified.
ICSI is recommended following a comprehensive clinical evaluation and diagnostic assessment at an established fertility clinic in Siliguri or a preferred medical facility.
Here are the clinical indications commonly evaluated when considering ICSI treatment:
When spermatozoa exhibit reduced forward progression or impaired mobility, natural fertilization can be restricted. Fertility specialists may recommend ICSI in such cases to select individual motile spermatozoa and microinject them directly into mature oocytes.
Oligospermia refers to a reduced concentration of sperm in the ejaculate, which can hinder natural fertilization and conventional IVF insemination. ICSI assists in managing low sperm counts by utilizing specialized microscopic techniques to isolate and utilize available spermatozoa for fertilization.
Teratospermia involves a high percentage of spermatozoa with structural or morphological variations, which can affect natural binding and penetration of the oocyte shell. ICSI bypasses natural sperm-shell penetration hurdles by directly delivering a selected spermatozoon into the oocyte cytoplasm.
In cases involving prior conventional IVF cycles with unexpected fertilization failure, ICSI is frequently incorporated into subsequent treatment planning to support fertilization outcomes under controlled laboratory conditions.
When azoospermia (absence of sperm in the ejaculate due to obstructive or non-obstructive factors) is present, spermatozoa can be surgically retrieved using advanced techniques (such as TESA or PESA) and utilized exclusively with ICSI for fertilization.
The presence of immune factors or anti-sperm antibodies in seminal fluid or reproductive tracts can interfere with natural sperm function. ICSI helps address these immunological barriers by directly isolating and injecting healthy spermatozoa into the oocyte.
ICSI follows a structured clinical protocol integrated with standard in vitro fertilization procedures. Here are the procedural stages:
The treatment begins with an initial clinical consultation at an established fertility center. Comprehensive diagnostic evaluations, including comprehensive hormone panels, pelvic ultrasounds, and semen analyses, are performed for both partners to guide personalized treatment planning.
Controlled ovarian stimulation is achieved using gonadotropin medications (such as FSH and LH analogues) to support multifollicular development. A final maturation trigger injection (hCG or GnRH agonist) is administered approximately 36 hours prior to oocyte retrieval to induce final oocyte maturation.
Oocyte retrieval is performed under sedation or anesthesia via transvaginal ultrasound guidance. A specialized aspiration needle collects follicular fluid containing mature oocytes from the ovaries under sterile laboratory conditions.
A fresh semen sample is provided and processed using laboratory washing techniques to isolate motile spermatozoa. In cases of obstructive or non-obstructive azoospermia, surgical sperm retrieval methods (such as TESA or PESA) may be performed to obtain testicular spermatozoa.
During ICSI, an embryologist immobilizes and selects a single spermatozoon using specialized microscopic equipment and gently injects it directly into the cytoplasm of a mature oocyte to initiate fertilization.
Injected oocytes are maintained in specialized laboratory incubators for 5 to 7 days, allowing embryologists to monitor cleavage and development through to the blastocyst stage.
A selected embryo is transferred into the uterine cavity using a fine, flexible catheter under ultrasound visualization, following established clinical protocols.
A quantitative serum beta-hCG blood test is performed 10 to 14 days following embryo transfer to evaluate clinical outcomes and confirm pregnancy status.
ICSI is an established reproductive procedure utilized to address male factor infertility and complex fertilization challenges. At Newlife Fertility Center , we understand the emotional and clinical significance of fertility care. We provide structured ICSI treatment by combining professional clinical expertise, advanced laboratory infrastructure, and compassionate patient support:
Our multidisciplinary team comprises qualified fertility specialists, embryologists, and dedicated nursing staff, ensuring comprehensive clinical management and guidance throughout the ICSI treatment journey.
Our clinical protocols are supported by advanced andrology and embryology laboratory equipment designed to maintain strict quality control and support precise microinjection procedures.
We prioritize detailed diagnostic assessments of individual health profiles to develop customized treatment plans. Our care model emphasizes transparency and clear communication at every stage of the process.
We provide supportive counseling resources before and during treatment to assist patients in navigating the emotional dimensions of assisted reproductive care in a compassionate environment.